Remove 2030 Remove Drug Pricing Remove Vaccines
article thumbnail

STAT+: Report: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players

STAT

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

article thumbnail

Some action points for the next PM

Express Pharma

Drug prices crash post-patent loss, due to this competition, which is good for patients but leaves drug makers struggling with thin profit margins. India’s traditional strength lies in small molecule chemical-based drugs which is why not too many companies focus on biologics.

article thumbnail

ESG Top Trends: Macroeconomic trends

Pharmaceutical Technology

Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. According to the World Health Organization (WHO), two billion people lack access to essential or basic drugs.